Compare LYFT & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYFT | LNTH |
|---|---|---|
| Founded | 2007 | 1956 |
| Country | United States | United States |
| Employees | 3913 | N/A |
| Industry | Business Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.6B |
| IPO Year | 2019 | 2014 |
| Metric | LYFT | LNTH |
|---|---|---|
| Price | $14.90 | $99.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 6 |
| Target Price | $20.07 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 9.0M | 901.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11250.00 | N/A |
| EPS | 0.16 | ★ 2.91 |
| Revenue | ★ $6,316,261,000.00 | $343,374,000.00 |
| Revenue This Year | $17.33 | N/A |
| Revenue Next Year | $12.29 | $14.19 |
| P/E Ratio | $92.19 | ★ $34.27 |
| Revenue Growth | ★ 9.16 | 3.62 |
| 52 Week Low | $12.46 | $49.67 |
| 52 Week High | $25.54 | $111.86 |
| Indicator | LYFT | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 40.35 |
| Support Level | $12.85 | $98.81 |
| Resistance Level | $15.15 | $101.24 |
| Average True Range (ATR) | 0.52 | 0.45 |
| MACD | -0.12 | -0.03 |
| Stochastic Oscillator | 21.10 | 12.13 |
Lyft is the second-largest ride-sharing service provider in North America, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury rides. Beyond ride-hailing, Lyft has entered the bike- and scooter-share market to offer multimodal transportation options.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.